Last reviewed · How we verify
Rifampin containing regimen
Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.
Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase. Used for Tuberculosis, Prophylaxis of Mycobacterium tuberculosis infection.
At a glance
| Generic name | Rifampin containing regimen |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Bacterial RNA polymerase inhibitor |
| Target | bacterial RNA polymerase beta subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the transcription of essential bacterial genes, ultimately leading to the death of the bacteria. Rifampin is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including Mycobacterium tuberculosis.
Approved indications
- Tuberculosis
- Prophylaxis of Mycobacterium tuberculosis infection
Common side effects
- Hepatotoxicity
- Thrombocytopenia
- Hemolysis
Key clinical trials
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (PHASE3)
- ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (PHASE2)
- Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis (PHASE3)
- Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection (PHASE2)
- INSTI's For The Management of HIV-associated TB (PHASE2)
- A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
- ATORvastatin in Pulmonary TUBerculosis (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifampin containing regimen CI brief — competitive landscape report
- Rifampin containing regimen updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI